US EditionPublished • loading... • Updated
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies
Summary by Post Register
1 Articles
1 Articles
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies
DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), and Xcellon Biologics, a U.S.-based contract development and manufacturing organization…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
